Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shile Huang

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
Current Opinion in Pharmacology|August 7, 2003
Targeting mTOR signaling for cancer therapyShile Huang, Peter J Houghton
Toxicology Letters|December 16, 2017
Maduramicin-activated protein phosphatase 2A results in extracellular signal-regulated kinase 1/2 inhibition, leading to cytotoxicity in myocardial H9c2 cellsXin Chen, Shanxiang Jiang, Shile Huang
Anti-Cancer Agents in Medicinal Chemistry|September 4, 2010
Updates of mTOR inhibitorsHongyu Zhou, Yan Luo, Shile Huang
Free Radical Biology & Medicine|August 16, 2008
Cadmium activates the mitogen-activated protein kinase (MAPK) pathway via induction of reactive oxygen species and inhibition of protein phosphatases 2A and 5Long Chen, Lei Liu, Shile Huang
Current Drug Targets|October 20, 2010
The targets of curcuminHongyu Zhou, Christopher S Beevers, Shile Huang
Molecular Cancer|February 1, 2017
Understanding of leukemic stem cells and their clinical implicationsXuefei Wang, Shile Huang, Ji-Long Chen
Anti-Cancer Agents in Medicinal Chemistry|January 1, 2013
Hitting the golden TORget: curcumin's effects on mTOR signalingChristopher S Beevers, Hongyu Zhou, Shile Huang
Journal of Applied Toxicology : JAT|October 20, 2017
Maduramicin induces apoptosis and necrosis, and blocks autophagic flux in myocardial H9c2 cellsXin Chen, Long Chen, Shanxiang Jiang, et al.
Anti-Cancer Agents in Medicinal Chemistry|January 1, 2013
Molecular evidence of cryptotanshinone for treatment and prevention of human cancerWenxing Chen, Yin Lu, Guangying Chen, et al.
Cancer Biology & Therapy|July 25, 2003
Rapamycins: mechanism of action and cellular resistanceShile Huang, Mary-Ann Bjornsti, Peter J Houghton
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
Current Opinion in Pharmacology|August 7, 2003
Targeting mTOR signaling for cancer therapyShile Huang, Peter J Houghton
Toxicology Letters|December 16, 2017
Maduramicin-activated protein phosphatase 2A results in extracellular signal-regulated kinase 1/2 inhibition, leading to cytotoxicity in myocardial H9c2 cellsXin Chen, Shanxiang Jiang, Shile Huang
Anti-Cancer Agents in Medicinal Chemistry|September 4, 2010
Updates of mTOR inhibitorsHongyu Zhou, Yan Luo, Shile Huang
Free Radical Biology & Medicine|August 16, 2008
Cadmium activates the mitogen-activated protein kinase (MAPK) pathway via induction of reactive oxygen species and inhibition of protein phosphatases 2A and 5Long Chen, Lei Liu, Shile Huang
Current Drug Targets|October 20, 2010
The targets of curcuminHongyu Zhou, Christopher S Beevers, Shile Huang
Molecular Cancer|February 1, 2017
Understanding of leukemic stem cells and their clinical implicationsXuefei Wang, Shile Huang, Ji-Long Chen
Anti-Cancer Agents in Medicinal Chemistry|January 1, 2013
Hitting the golden TORget: curcumin's effects on mTOR signalingChristopher S Beevers, Hongyu Zhou, Shile Huang
Journal of Applied Toxicology : JAT|October 20, 2017
Maduramicin induces apoptosis and necrosis, and blocks autophagic flux in myocardial H9c2 cellsXin Chen, Long Chen, Shanxiang Jiang, et al.
Anti-Cancer Agents in Medicinal Chemistry|January 1, 2013
Molecular evidence of cryptotanshinone for treatment and prevention of human cancerWenxing Chen, Yin Lu, Guangying Chen, et al.
Cancer Biology & Therapy|July 25, 2003
Rapamycins: mechanism of action and cellular resistanceShile Huang, Mary-Ann Bjornsti, Peter J Houghton
Pageof 15